Glenn M. Marshall

This study identifies the FBXL12-FANCD2 pathway as a vulnerability in MYCN-driven neuroblastoma, showing its role in replication stress tolerance and potential as a therapeutic target.

This study identifies UNSW-SC-22 as a novel MYC/MYCN-targeting molecule that crosses the blood-brain barrier and shows potent preclinical efficacy in medulloblastoma.

This paper shows RNA-seq can detect most mutations found by WGS in pediatric tumors and provides additional insights into their pathogenicity.

This paper genomically characterizes 261 pediatric cancer patient-derived xenograft models to guide rational clinical trial design and drug development.